Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Digirad Corp Receives U.S. FDA 510(k) Market Clearance For Expanded Uses Of ergo(TM) Imaging System


Thursday, 31 Jan 2013 07:30am EST 

Digirad Corp announced that it has received U.S. FDA 510(k) market clearance to further expand the clinical flexibility of the ergo Imaging System for applications throughout the hospital, including the areas of nuclear medicine, surgery and women's health. The clearance includes indications for lymphatic scintigraphy and parathyroid scintigraphy, both nuclear diagnostic imaging tests, and to aid in the evaluation of lesions in the breast and other small body parts. The ergo can also be used intra-operatively when protected by sterile drapes. When used for breast imaging, the ergo System is indicated to serve as an adjunct to mammography or other primary breast imaging modalities. 

Company Quote

4.04
0.07 +1.76%
24 Dec 2014